Van beleggers
voor beleggers
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
  • Word abonnee
  • Inloggen

    Inloggen

    • Geen account? Registreren

    Wachtwoord vergeten?
Home  /  Forum  /  Celyad  /  CYAD-200 Series – shRNA-based Allogeneic CAR-Ts

Ontvang nu dagelijks onze kooptips!

word abonnee

Aandeel Celyad BRU:CYAD.BL, BE0974260896

  • 0,330 23 apr 2024 12:30
  • +0,010 (+2,97%) Dagrange 0,310 - 0,339
  • 16.063 Gem. (3M) 25,1K

CYAD-200 Series – shRNA-based Allogeneic CAR-Ts

4 Posts
| Omlaag ↓
  1. [verwijderd] 22 november 2019 20:36
    CYAD-200 Series – shRNA-based Allogeneic CAR-Ts

    The Company continues to pursue the development of the proprietary non-gene edited allogeneic shRNA SMARTvector platform and progress towards filing IND applications for the CYAD-200 series of shRNA-based allogeneic CAR-T candidates, including CYAD-211, the Company’s CAR-T therapy targeting B-cell maturation antigen (BCMA) for the treatment of multiple myeloma.

    Bron: www.trivano.com/aandeel/celyad-announ...
  4. Hautfourno 8 februari 2020 10:25
    The Belgian company Celyad has released the first interim clinical efficacy data for an off-the-shelf CAR T-cell immunotherapy in solid tumors.

    The interim results come from an ongoing phase I trial in patients with colorectal cancer. Of the 12 patients given Celyad’s CAR T-cell immunotherapy so far, six have seen their tumors shrink. The therapy has also shown no evidence of causing graft-versus-host disease, a condition where foreign immune cells attack the host body.

    Celyad’s CAR T-cell immunotherapy is aimed to overcome the drawbacks of CAR T-cell immunotherapies already in the market such as Kymriah and Yescarta. These therapies require immune T-cells to be extracted from patients and transported to labs when they can be genetically modified to fight cancer. This makes manufacturing hard and costly. Celyad’s off-the-shelf CAR-T therapy, on the other hand, would be ready to use in advance.

    “Deriving cells from healthy donors as opposed to late-stage cancer patients also means that the yield and quality of harvested cells are higher, which should translate to lower production costs and fewer potential manufacturing failures,” Filippo Petti, CEO of Celyad, told me.

    Going forward, another three patients will be enrolled in the first stage of the trial, and further results are expected in early 2020. Celyad then plans to expand the trial in mid-2020, with the total enrollment estimated to reach 36 patients.

    car-t immunotherapy celyad off-the-shelf
    There are other off-the-shelf CAR-T therapies in development, such as those of the French company Cellectis. According to David Gilham, Celyad’s VP of Research and Development, Celyad’s technology has a series of key advantages. First, it can target solid tumors. Second, Celyad’s therapy needs only one step to genetically modify its T-cells instead of the several steps that it takes for other companies to modify their T-cells.

    While CAR T-cell immunotherapies have revolutionized the treatment of blood cancer, the field as a whole still has a lot of potential in other types of cancer. According to Petti, the development of off-the-shelf options is going to help companies to overcome obstacles to the adoption of cell therapies. These obstacles include high costs and regulatory difficulties in the manufacturing process.
4 Posts
|Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Premium drie voorbeelden van IEX Premium: de exclusieve content op de site, de app op een smartphone en IEX Magazine.

Benieuwd naar onze analyses en kooptips?

Word nu abonnee van IEX en krijg onbeperkt toegang tot onze (koop)tips en succesvolle modelportefeuilles. Nu 3 maanden voor slechts €19,95! Profiteer van 58% korting!

Word abonnee

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links

Meld u aan voor de dagelijkse Beursupdate

Dagelijks een update van het laatste beursnieuws en beleggingskansen in uw mailbox!